One Year Study of Rifaximin Delayed Release (DR) Tablets in Crohn's Disease

Stopped early · Phase 3 · Has a placebo group

Conditions studied: Crohn's Disease

In brief

The primary objective is to determine the efficacy of rifaximin DR also referred to as Extended Intestinal Release (EIR) tablets vs. placebo for the induction of clinical remission and endoscopic response following 16 weeks of treatment in participants presenting with active moderate Crohn's disease. A key secondary objective is to evaluate clinical and endoscopic remission following an additional 36 weeks of treatment.

Key facts

Study ID
NCT02240121
Run by
Bausch Health Americas, Inc.
People needed
80
Starts
2014-08-21
Expected to finish
2017-08-16
Last updated by the study team
2019-09-10

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.